Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: In progressive multiple sclerosis (MS), glial activation is thought to be a relevant mechanism of disability progression. Therefore, in vivo assessment of the glial cell activity is, in the emerging treatment era of primary progressive MS (PPMS), more important than ever. Objectives: To test the association of cerebrospinal fluid (CSF) and serum markers of glial activation in PPMS patients; including glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (CHI3L1), soluble variant of triggering receptor expressed on myeloid cells 2 (sTREM2) and marker of neuroaxonal damage (Neurofilament light chain, NfL) as well as clinical severity. Methods: CSF and serum samples from PPMS patients were collected in the MS-centers at Universities of Freiburg (n= 49), Ulm (n= 27), Muenster (n= 11) and Rostock (n= 6). sTREM2 and CHI3L1 levels were measured using the previously reported ELISA assays, while NfL and GFAP were measured using SIMOA assays. Clinical data included age, gender, disease duration, treatment status and Expanded Disability Status Scale (EDSS). Results: 93 CSF samples and 71 matching serum samples were analyzed. The median age of patients was 49 years and disease duration 4.5 years. GFAPserum correlated with EDSS after correction for age (β= 0.3. p= 0.001). Furthermore, EDSS was higher in patients with a GFAPserum level ≥ 151.7 pg/ml compared to patients with GFAPserum below this cut-off (5.5 vs 4.0, p= 0.009). Other markers did not correlate with the clinical severity. Moreover, we found a correlation between NfLCSF and GFAPCSF, sTREM2 and CHI3L1 (ρ = 0.4 for GFAPCSF and sTREM2, ρ = 0.3 for CHI3L1, p < 0.01 for sTREM2 and CHI3L1 and < 0.001 for GFAPCSF). CHI3L1 did not correlate with GFAPCSF but with sTREM2 (ρ = 0.4, p < 0.01). Discussion: The correlation between the glial activation markers in CSF with the markers of neuroaxonal demise supports the notion of the glial involvement in PPMS. The positive correlation between GFAPCSF with disease duration and GFAPserum with the clinical severity of the disease may highlight a particular role of the astrocytes in PPMS and mark the potential of GFAPserum as a disease severity marker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167 · cited 1×
“In all patients, the diagnosis has been revised according to theMcDonald criteria from 2017 (27) after careful exclusion of relevant differential diagnoses.”
MethodNeurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Astrocytes: Biology and pathology
Sofroniew, M. V., & Vinters, H. V. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0619-8 · Cited by 5,196
Debris clearance by microglia: an essential link between degeneration and regeneration
Neumann, H., Kotter, M. R., & Franklin, R. J. M. (2008) · Brain · doi:10.1093/brain/awn109 · Cited by 1,111
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · cited 1×
“CSF and Serum Sample Processing A standardized protocol for CSF and serum collection was applied as previously recommended (29).”
MethodSelf-citationTREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 2×
“sTREM2wasmeasured using the previously reported ELISA using the MSD Platform (21).”
MethodSelf-citationLoss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684 · cited 1×
“Like the astrocytes, the activated microglial release different cytokines (IL-1, Il-6, and TNF-α) as well as NO and ROS leading to exacerbation of inflammatory cascade, to attraction of inflammatory cells from blood and also to mitochondrial dysfunction, a significant mechanism in the disease progression in PMS (2, 3,…”
BackgroundBiomarkers of traumatic injury are transported from brain to blood via the glymphatic system.
Plog, B. A., Dashnaw, M. L., Hitomi, E., Peng, W., Liao, Y., Lou, N., Deane, R., & Nedergaard, M. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3742-14.2015 · Cited by 525 · cited 1×
“Moreover, the GFAP, as well as other markers, might be transported to blood directly via the glymphatic system as shown recently in murine models of traumatic brain injury (36).”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Cited by
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Self-citationBenedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Self-citationMeier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.5250 · Cited by 289
Self-citationCzeiter, E., Amrein, K., Gravesteijn, B. Y., Lecky, F., Menon, D. K., Mondello, S., Newcombe, V. F. J., Richter, S., Steyerberg, E. W., Vyvere, T. V., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102785 · Cited by 280
Trapecar, M., Wogram, E., Svoboda, D., Communal, C., Omer, A., Lungjangwa, T., Sphabmixay, P., Velazquez, J., Schneider, K., Wright, C. W., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd1707 · Cited by 176
Barro, C., Healy, B. C., Liu, Y., Saxena, S., Paul, A., Polgar-Turcsanyi, M., Guttmann, C. R. G., Bakshi, R., Kropshofer, H., Weiner, H. L., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200052 · Cited by 176
“Moreover, consistently with previous findings, both biomarkers were positively associated with the EDSS score.(20,48,49)”
ResultIncreased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression
Michel, M., Fiebich, B. L., Kuzior, H., Meixensberger, S., Berger, B., Maier, S., Nickel, K., Runge, K., Denzel, D., Pankratz, B., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01423-6 · Cited by 79
Yalachkov, Y., Schäfer, J. H., Jakob, J., Friedauer, L., Steffen, F., Bittner, S., Foerch, C., & Schaller-Paule, M. A. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200045 · Cited by 49
TREM2 expression in the brain and biological fluids in prion diseases
Diaz-Lucena, D., Kruse, N., Thüne, K., Schmitz, M., Villar-Piqué, A., da Cunha, J. E. G., Hermann, P., López-Pérez, Ó., Andrés-Benito, P., Ladogana, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02296-1 · Cited by 32
Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis
Niiranen, M., Kontkanen, A., Jääskeläinen, O., Tertsunen, H.-M., Selander, T., Hartikainen, P., Huber, N., Solje, E., Haapasalo, A., Kokkola, T., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103280 · Cited by 25
Ammitzbøll, C., Dyrby, T. B., Börnsen, L., Schreiber, K., Ratzer, R., Romme Christensen, J., Iversen, P., Magyari, M., Lundell, H., Jensen, P. E. H., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104854 · Cited by 20
Brieva, L., Calles, C., Landete, L., & Oreja-Guevara, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543649 · Cited by 16
Metadata
- Authors
- Abdelhak, A., Hottenrott, T., Morenas-Rodríguez, E., Suárez-Calvet, M., Zettl, U. K., Haass, C., Meuth, S. G., Rauer, S., Otto, M., Tumani, H., & Huss, A.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2019-03-26
- Volume
- 10
- Pages
- 280-280
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2925266449
- Cited by
- 141
- References
- 18
- FWCI
- 9.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.